LUMINAL B IS THE MOST COMMON BREAST CANCER SUBTYPE IN PATIENTS OF ALMATY ONCOLOGY CENTER Текст научной статьи по специальности «Фундаментальная медицина»

Received: 15 September 2021 / Accepted: 26 September 2021 / Published online: 31 October 2021

DOI 10.34689/SH.2021.23.5.011 UDC 618.19-006.55

LUMINAL B IS THE MOST COMMON BREAST CANCER SUBTYPE IN PATIENTS OF ALMATY ONCOLOGY CENTER

Maryam Zabihi 1, Mahboba Islami 2,

Natalya Glushkova 3, https://orcid.org/0000-0003-1400-8436, Ainash Altayeva 4

1 Herat University, Medical Faculty, Department of histopathology, Herat, Afghanistan;

2 Kabul University of Medical science, Department of anesthesiology, Kabul, Afghanistan;

3 Al-Farabi Kazakh National University, Department of Epidemiology, Biostatistics & Evidence Based Medicine, Almaty, Republic of Kazakhstan;

4 Al-Farabi Kazakh National University, Department of Clinical Disciplines, Almaty, Republic of Kazakhstan.

Abstract

Introduction: Breast cancer is a heterogenous group of disease that is most prevalent malignant disease of female population of Kazakhstan.

Aim of study: to find most common pathologic type and molecular subtype of breast cancer cases in the Almaty oncology center and evaluate association among molecular subtype with different pathological type, tumor characteristics and Participant's criteria

Materials and methods: A cross sectional-study was conducted at Almaty oncology center, Kazakhstan between January and December 2020. We studied medical records of 818 breast cancer cases and included data of 622 cases in this study. Data about pathologic type, grade, stage, estrogen (ER), progesterone (PR) HER2 overexpression and ki67 were analyzed. Molecular subtype determination in this center was done by using immunohistochemistry and this Criteria ('Luminal A-like' ER/PR +, HER2-, Ki67 low) ('Luminal B-like' ER/PR +, HER2 ± and Ki67 high) ('HER2-positive' HER2+ ER and PR -) (Triple-negative ER and PR absent HER2-). The association were evaluated among molecular subtype with different pathological type, tumor characteristics and Participant's criteria using Chi square test

Results: Most common pathologic type of tumor in this study was NST (85.3%), ILC (3.8%) and DCIS (2.1%) respectively. Most prevalent molecular subtype of tumors: Luminal B (57.6%), luminal A (22.2%), triple negative (12%) and HER/2 enriched (8.3%). There was statistically significant association (p-value <0.05) between Molecular subtype and pathologic type of tumor, grade, stage, size, hormone receptors, HER/2 over expression and mitotic rate.

Conclusion: luminal B was the most prevalent subtype and HER2 positive was the least prevalent and it is better to work more for finding better treatment for luminal B. A significant association among molecular subtype of tumor and pathologic subtype, grade, stage, size, hormone receptors, hEr/2 over expression and mitotic rate were found. Key words: breast cancer, molecular subtype, immunohistochemistry, Almaty.

Резюме

LUMINAL B - САМЫЙ РАСПРОСТРАНЕННЫЙ ПОДТИП РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ У ПАЦИЕНТОВ АЛМАТИНСКОГО ОНКОЛОГИЧЕСКОГО ЦЕНТРА

Марьям Забихи1, Махбоба Ислами2,

Наталья Глушкова3, https://orcid.org/0000-0003-1400-8436, Айнаш Алтаева4

1 Университет Герата, Медицинский факультет, Кафедра гистопатологии, г. Герат, Афганистан;

2 Кабульский университет медицинских наук, Кафедра анестезиологии, г. Кабул, Афганистан;

3 Казахский национальный университет имени Аль-Фараби, Кафедра эпидемиологии, биостатистики и доказательной медицины, г. Алматы, Республика Казахстан;

4 Казахский национальный университет имени Аль-Фараби, Кафедра клинических дисциплин, г. Алматы, Республика Казахстан.

Введение: Рак груди - разнородная группа заболеваний, которая является наиболее распространенным злокачественным заболеванием женского населения Казахстана.

Цель исследования: найти наиболее распространенный патологический тип и молекулярный подтип случаев рака груди в онкологическом центре Алматы в течение 2020 года и оценить связь между молекулярным подтипом с различным патологическим типом, характеристиками опухоли и критериями участника.

Материалы и методы: это поперечное аналитическое и описательное исследование с января 2020 года по декабрь 2020 года было проведено в онкологическом центре Алматы, Казахстан. Мы изучили медицинские записи о 818 случаях рака груди и включили в это исследование данные о 622 случаях. Были проанализированы данные о патологическом типе, степени, стадии, гиперэкспрессии HER2 эстрогена (ER), прогестерона (PR) и ki67. Определение молекулярного подтипа в этом центре проводилось с использованием иммуногистохимии и следующих критериев («Luminal A-like» ER / PR +, HER2-, Ki67 low) («Luminal B-like» ER / PR +, HER2 ± и Ki67 high) («HER2-

положительный» HER2 + ER и PR -) (тройной отрицательный ER и PR без HER2-). Связь оценивалась среди молекулярных подтипов с различным патологическим типом, характеристиками опухоли и критериями участника с использованием критерия хи-квадрат.

Результаты. Наиболее частым патологическим типом опухоли в этом исследовании был NST (85,3%), ILC (3,8%) и DCIS (2,1%) соответственно. Наиболее распространенный молекулярный подтип опухолей: просвет B (57,6%), просвет A (22,2%), тройной отрицательный (12%) и обогащенный HER / 2 (8,3%). Обнаружена статистически значимая связь (значение p <0,05) между молекулярным подтипом и патологическим типом опухоли, степенью, стадией, размером, рецепторами гормонов, сверхэкспрессией HER / 2 и скоростью митоза.

Заключение: просвет B был наиболее распространенным подтипом, а HER2-положительный - наименее распространенным. Была обнаружена значимая связь между молекулярным подтипом опухоли и патологическим подтипом, степенью, стадией, размером, рецепторами гормонов, сверхэкспрессией HER 2 и скоростью митоза.

Ключевые слова: рак груди, молекулярный подтип, иммуногистохимия, Алматы.

Туйшдеме

LUMINAL B - АЛМАТЫ ОНКОЛОГИЯЛЫК ОРТАЛЫГЫНЫИ ПАЦИЕНТТЕР1НДЕ СУТ БЕЗ1 ОБЫРЫНЫН ЕИ К9П ТАРАЛГАН К1Ш1 TYPI

Марьям Забихи1, Махбоба Ислами2,

Наталья Глушкова3, https://orcid.org/0000-0003-1400-8436, Айнаш Алтаева4

1 Герат университет!, Медицинальщ факультет, Гистопатология кафедрасы, Герат к-, Ауганстан;

2 Медициналык гылымдар Кабул университет^ Анестезиология кафедрасы, Кабул к-, Ауганстан;

3 Эл-Фараби атындагы Казак, ултты^ университет!, Эпидемиология, биостатистика жэне дэлелд1 медицина кафедрасы, Алматы к-, Казахстан Республикасы;

4 Эл-Фараби атындагы Казак, ултты^ университет!, Клиникалы^ пэндер кафедрасы, Алматык К-, Казахстан Республикасы;

К1р1спе: Су безУч катерлi юИ-бул ^азакстан 0йелдерiнiн еч кеп таралган катерлi ауруы болып табылатын аурулардыч туо тобы.

Зерттеу максаты: 2020 жылы Алматы каласыныч Онкологиялык орталыгында сYт безi обырыныч еч кеп таралган патологиялык тур^ жэне молекулярлык кiшi тYрiн табу жэне молекулярлык кiшi TYрi мен тYрлi патологиялык типщ, iсiк сипаттамаларыныч жэне катысушы елшемдерiнiч арасындагы байланысты багалау.

Материалдар мен эд!стер: бул келденеч аналитикалык жэне сипаттамалык зерттеу 2020 жылдыч качтарынан 2020 жылдыч желтоксанына дейiн ^азакстан, Алматы онкологиялык орталыгында жYргiзiлдi. Бiз сYT безi катерлi iсiгiнiч 818 жавдайы туралы медициналык жазбаларды зерттедiк жэне осы зерттеуге 622 жавдай туралы мэлiметтердi енгiздiк. HER2 эстрогеннiч (ER), прогестеронныч (PR) жэне ki67 патологиялык TYрi, дэрежесi, сатысы, гиперэкспрессиясы туралы деректер талданды. Бул орталыктагы молекулалык кiшi TYPДi аныктау иммуногистохимия жэне келес критерийлер бойынша жYргiзiлдi («Luminal A-like» ER / PR +, HER2-, Ki67 low) («Luminal B-like» ER / PR +, HER2 ± и Ki67 high) ("HER 2-оч" HER2 + ER жэне PR -) (HE^-жок Yштiк терю ER жэне PR). Байланыс молекулалык кш TYрлер арасында эр TYрлi патологиялык типтермен, iсiк сипаттамасымен жэне катысушы критерийлерiмен хи-квадрат критерийiн колдана отырып багаланды.

Нэтижелер!. Бул зерттеуде юкщ жиi кездесетiн патологиялык TYрi сэйкесiнше NST (85,3%), ILC (3,8%) жэне DCIS (2,1%) болды. Iсiктердiч еч кеп таралган молекулалык кш TYрi: в люменi (57,6%), а люмен (22,2%), Yштiк терiс (12%) жэне HER / 2 (8,3%) байытылган. Молекулалык кш тип пен юкщ патологиялык TYрi, дэрежесi, сатысы, мелшер^ гормон рецепторлары, HER / 2 шамадан тыс экспрессиясы жэне митоз жылдамдыгы арасындагы статистикалык мачызды байланыс (p <0,05 мэнi) табылды.

Корытынды: в люменi еч кеп таралган кiшi тип болды, ал HER2 оч - еч аз таралган. Iсiктiч молекулалык кiшi TYрi мен патологиялык кiшi TYрi, дэрежеа, сатысы, мелшерi, гормон рецепторлары, HER / 2 суперэкспрессиясы жэне митоз жылдамдыгы арасында мачызды байланыс табылды.

TYurndi свздер: CYm без1н1ц цатерл! 1с1г1, молекулалык к1ш1 mYpi, иммуногистохимия, Алматы.

Bibliographic citation:

Zabihi M., Islami M., Glushkova N., Altayeva A. Luminal B is the most common breast cancer subtype in patients of Almaty oncology center // Nauka i Zdravookhranenie [Science & Healthcare]. 2021, (Vol.23) 5, pp. 93-100. doi 10.34689/SH.2021.23.5.011

Забихи М., Ислами М., Глушкова Н., Алтаева А. Luminal B - cамый распространенный подтип рака молочной железы у пациентов Алматинского онкологического центра // Наука и Здравоохранение. 2021. 5(Т.23). С. 93-100. doi 10.34689/SH.2021.23.5.011

Забихи М., Ислами М., Гпушкова Н., Алтаева А. Luminal B - Алматы онкологиялык орталыгыныч пациенттерще сут безi обырыныч еч кеп таралган кш TYрi // Гылым жэне Денсаулык сактау. 2021. 5 (Т.23). Б. 93-100. doi 10.34689/SH.2021.23.5.011

Introduction

Breast cancer is the most prevalent cause of cancer death in women [1] and the second cause of cancer death in both sexes after Lung cancer in Asia [2] For several years, cancer has been the third cause of death in Kazakhstan [3, 4] BC is the most common malignant disease among the female population of this country [4]. It has had highest incidence of malignant disease in both sexes since 2004. During last years, breast cancer incidence in Kazakhstan increase, although mortality tended to decrease [5, 6]

Breast cancer is a heterogenous group of disease with different risk factors, natural history and response to treatment. The most common classification for breast cancer are pathologic classification and molecular sub typing based on gene expression pattern. Molecular classification has prognostic value in addition to determining treatment plan. There is a simplified classification for molecular subtyping based on IHC marker according to the 2015 St Gallen Consensus Conference. This classification divides breast carcinoma into luminal A, luminal B, HER2+, and triple-negative sub types based on expression of ER, PgR, HER2, and Ki-67.

Gold standard in breast lesions diagnosis is histologic classification [7] and Most common types of invasive breast cancer is carcinoma of non-specific type (NST) (70% - 75%) and Invasive lobular carcinomas (ILC) (5% - 15%) [8] and other types are less common.

In the present study, we aimed to research on the prevalence of breast cancer subtypes in patients referred to Almaty oncology center and finding association between molecular subtype of BC with different criteria of breast cancer, and characteristics of patients in Almaty city.

Material and methods

Type of study and Participants: A cross sectional study was done on breast cancer cases of female that referred to Almaty oncology center during the year 2020 (from first of January to end of December 2020).

Inclusion criteria: female with breast cancer referred to Almaty oncology center during the year 2020 with recorded results of pathologic and immunohistochemical test in Almaty oncology center.

Exclusion criteria: male patients and patients with incomplete recorded results of pathologic and immunohistochemical test in Almaty oncology center and patients referred before or after year 2020

Ethical consideration: This research was conducted with prior approval from Al-Farabi Kazakh national university ethical committee (IRB-286/08.04.2021)

Data source: Information about breast cancer case was requested from department of statistics of Almaty oncology center then Information about histopathologic examination and IHC result were added to previous data from records in IHC laboratory. Cases without pathologic diagnosis and IHC test results were omitted.

Specimen preparation: The specimens of Almaty oncology center, were taken from patients in Almaty oncology center via core needle biopsy or resected tumor via surgery in Pathological Bureau during year 2020 (from first of January to end of December).

Histological preparation of slides was done in Pathological Bureau and immunohistochemical preparation

and study was done in IHC laboratory of Almaty oncology center. For identification of tumor type and histologic grade based on WHO classification [9] hematoxylin and eosin stains were used. Immunohistochemical staining was done by VENTANA automatic machine and all regents used in staining are products of this company. Tumors with > 1% positively nuclear-stained cells were considered positive for both ER and PgR expression [10]. Allred scoring system used for evaluation of ER and PR expression. Besides, HER2 positive was scored if the staining occurred for > 10% of tumor cells [11] ki 67 marker was product of VENTANA company and used based on manufacturer instruction. Tumors with > 20% nuclear positivity in staining considered high-rate proliferation and tumors with <20% positivity considered low proliferation rate.

SISH test: The entire procedure was carried out on an automated staining system (VENTANA bench mark ULTRA Staining System) according to the manufacturer's instructions. Positive and negative controls were used for each staining run.

Statistical analysis: Statistical analysis was done by IBM SPSS statistic (version 26). Mean ± standard deviation was used for continuous variables and frequencies & percentages for categorical variables. Pearson chi square test and Fisher exact test were run for evaluating association between different categorical factors. In cases that frequency of each cell in contingency table was less than five in more than 20% of cells, fisher exact test was used instead of Pearson chi square test.

Result

The total number of patients that recourse to Almaty oncology center during the year 2020 was 818, 622 cases with available IHC test results were included in the study. Patients with incomplete tests result or medical records were excluded from this research.

Included women were from 23 different ethnicities with mean age of participants was 57.4± 13.10 range from (2493). grade II was more common (51.2%) than other grades and 60% were in stage II. 61% of tumors in this study had (2-5 cm) size in greater dimension. 94% of them did not have metastasis. More information about these criteria is presented in table number one. Carcinoma of non-specific type (NST) composed 85.3% of all tumors. More detail about percentage of different type of tumor is presented in figure 1. High percentage of tumors were ER/PgR positive (79.7%) and HER2 negative (79%) with high proliferation rate (75.6%). Details of immunohistochemical test results is presented in table 2. Most common intrinsic subtype of tumor was luminal B. percentage of each molecular subtype is presented in figure 2

Luminal A subtype has smaller size tumors in comparison to triple negative and HER/2 positive tumors

Because of important role of molecular sub types of breast cancer in determining plane of treatment and prognosis of disease, a chi square test was conducted for finding association of molecular subtypes with different clinical and immunohistochemical factors. P-value <0.05 considered significant. Pearson chi square test or fisher exact test was significant for association among molecular sub type of tumor and pathologic type of tumor, grade, stage, size, hormone receptors, HER/2 over expression and mitotic rate. Details are presented in table 3.

Table 1.

Social Characteristics of Patients and criteria of tumors (n= 622)_

Characteristics Count Percentage

Mean ± SD 57.4± 13.10

Ages(years) Min - Max 24-93

<50 195 31.4

>50 427 68.6

Kazakh 269 46.2

Ethnicity Russian 192 33

other 121 20.8

1 49 8.4

Histologic grade 2 298 51.2

3 235 40.4

0 17 3

1 116 20.7

Tumor stage 2 337 60.1

3 60 10.7

4 31 5.5

T0 20 3.5

T1 128 22.6

Tumor size T2 345 61

T3 19 3.4

T4 54 9.5

N0 65 10.5

N1 88 14.1

Lymph node status N2 25 4.0

N3 8 1.3

NX 436 70.1

Metastasis M0 531 94.0

M1 34 6.0

90 80 70 60

<D

if 50

c

<D

£ 40

<D CL

30 20 10 0

85,3

5,9

NST

-3,8 2,1

ILC DCIS

pathologic type of tumor

Figure 1 - pathologic types of tumors in 6 groups

Other rare type of BC

Tubular carcinoma

1

LCIS

2

Table 2.. Immunohistochemical test results (n=622

Characteristics Count Percentage

ER Negative (0 and 2) 154 25.1

(in Allred Low (3 and 4) 41 31.8

scoring Intermediate (5 and 6) 27 36.2

system) High (7 and 8) 391 63.8

PgR Negative (0 and 2) 218 36.3

(in Allred Low (3 and 4) 72 12

scoring Intermediate (5 and 6) 92 15.3

system) High (7 and 8) 218 36.3

HER2 Positive 121 21.0

Negative 455 79.0

Ki67 Low (<20%) 150 24.4

High (>20% ) 465 75.6

luminal A triple negative

molecular subtypes

Figure 2. Percentage of each molecular subtype.

Table 3. Association between Clinical and Immunohistochemical Factors with Intrinsic Molecular Subtypes.

Characteristics Luminal A Luminal B Triple negative HER2+ All cases Chi square P value

n (%) n (%) n (%) n (%) n (%) 3.909 0.271

Age (years) <50 32 (24.2) 113 (32.8) 22 (30.0) 18(36.0) 185 (30.9)

>50 100 (75.8) 232 (67.2) 50 (69.4) 32 (64.0) 414 (69.1)

Ethnicity Kazakh 58(47.2) 150(46.4) 26(37.7) 23(50.0) 257(45.8) 5.105 0.530

Russian 44(35.8) 103 (31.9) 29(42.0) 12 (26.1) 188(35.5)

Other 21(17.1) 70 (21.7) 14(20.3) 11(23.9) 116(20.7)

Grade 1 33 (27.0) 13 (3.9) 1 (1.4) 0 (0.0) 47 (8.2) 120.9 <0.001

2 73 (59.8) 185 (55.2) 24 (34.3) 14 (30.4) 296 (51.7)

3 16 (13.1) 137 (40.9) 45 (64.3) 32 (69.6) 230 (40.1)

Tumor size T0 5(4.3) 4 (1.3) 2 (2.9) 2(4.5) 13(2.4) 38.09 <0.001

T1 47 (40.2) 62 (19.5) 13 (18.8) 4(9.1) 126 (23.0)

T2 58 (49.6) 206 (64.8) 46 (66.7) 28 (63.6) 338 (61.7)

T3 2 (1.7) 11 (3.5) 3 (4.3) 2 (4.5) 18 (3.3)

T4 5 (4.3) 35 (11.0) 5 (7.2) 8 (18.2) 53 (9.7)

N N0 13 (9.8) 33 (9.6) 14 (19.4) 5 (10.0) 65 (10.9) 12.2 0.43

N1 15(11.4) 52 (15.1) 9 (12.5) 9 (18.0) 85 (14.2)

N2 5 (3.8) 15 (4.3) 3 (4.2) 2 (4.0) 25 (4.2)

N3 1 (0.8) 5 (1.4) 0 (0.0) 2 (4.0) 8 (1.3)

NX 98(74.2) 240 (69.6) 46 (63.9) 32 (64.0) 416 (69.4)

M M0 113 (96.6) 297 (93.7) 66 (95.7) 38 (86.4) 515 (93.8) 6.28 0.09

M1 4(3.1) 20 (6.6) 3 (4.3) 6 (13.6) 33 (6.0)

Stage 0 5 (4.3) 4(1.3) 0 (0.0) 2 (4.5) 11 (2.0) 52.235 <0.001

1 47 (40.2) 55 (17.4) 10 (15.2) 2 (4.5) 114 (20.9)

2 57 (48.7) 202 (63.7) 45 (68.2) 27 (61.4) 331 (60.8)

3 4 (3.4) 38 (12.0) 8 (12.1) 8 (18.2) 58 (10.7)

4 4 (3.4) 18 (5.7) 3 (4.5) 5 (11.4) 30 (5.5)

Pathologic sub type NST 102 (70.8) 305 (93.6) 68 (94.4) 42 (85.7) 517 (87.5) 46.97 <0.001

ILC 12 (8.3) 9 (2.8) 0 (0.0) 2 (4.1) 23 (3.9)

Other 30 (20.8) 12 (3.7) 4 (5.6) 5 (10.2) 51 (8.6)

Figure 3. Association of molecular subtype of tumor with pathologic type.

Discussion

Taking account to heterogenous nature of breast cancer, determining most common and less common BC types and associated factors are important for improving preventing programs . identification of most common and less common BC types help health care provider to guide investment in treatment researches. There is no study that evaluate most common cancer type in Almaty city and investigate association of different clinicopathological criteria with molecular subtype of tumors. Molecular subtype of tumor determine treatment plane. For example luminal cancers are treated by hormone therapy, HER2 positive tumors by targeted therapy and Based on available data BC is very common in Almaty city, there for study about cancer types is a must. For this reason we studied all female breast cancer cases referred to Almaty oncology center (main center for diagnosis of cancer for citizen of Almaty city) since first of January to end of December 2020 to determine pathologic and molecular subtype of tumors and find associated factors to molecular subtypes.

Pathologic type of tumors:

In gathered data there were 21 types of cancer. For better presentation we classified types that composed less than one percent of all cases, in a single group and called it

other rare type. NST with 523 cases was most prevalent type of cancer in this study that composed 85.3% of all cases. ILC and DCIS with 23(3.7%) and 13 (2.1%) cases have second and third position.

In previous studies, NST is most frequent type and ILC is second one, for example study of Abiltayeva and colleagues in North East of Kazakhstan [12], Al-thoubaity in Saudi Arabia [13], Caldarella and colleagues in Italy [14], Badowska-Kozakiewicz and teammates in Poland [15].

Molecular subtype of tumors:

In this study we found luminal B, most prevalent type (57.5%) of tumors. There is similar finding (56.5%) in study of Thang et al in Vietnam [16] and Mandaliya and colleagues in Australia (51%) [17]. Some authors like Fatemi et al [18], San et al [19] and Paramita and colleagues [20] found luminal B more prevalent than other types.

A study that was conducted in Semey and Pavlodar cities and include 253 cases from 10 years, reported luminal A is most prevalent. Difference in results may be due to different study setting or different ethnicity of participants. In our study 33% of participants are Russian while in their study this percentage is 58.1

APPENDIX A

Table A.1. Variable coding used for SPSS.

Variable coding

No Variable Code

1 Age <50 =1, >50 =2

2 Ethnicity Kazakh =1, Russian =2, other =3

3 Tumor size T0 =1, T1 =2, T2 =3, T3=4, T4=5

4 Lymph node invasion N0 =1, N1 =2, N2=3, N3=4, NX =0

5 Metastasis M0 =1, M1=2

6 Pathologic type of tumor NST =1, ILC =2, DCIS=3, Other=4

7 Histologic grade G1 =1, G2=2, G3=3

8 Stage I =1, II =2, III =3

9 Estrogen receptor status Negative =1, Positive =2

10 Estrogen expression level Negative =1, low =2, intermediate =3, high =4

11 Estrogen expression score Non =0, 2 = 2score, 3 = 3score, 4=4 score, 5 =5 score, 6 =6 score, 7= 7score, 8 = 8 score

12 Progesterone receptor status Negative =1, Positive =2

13 Progesterone expression level Negative =1, low =2, intermediate =3, high =4

14 Progesterone expression score Non =0, 2 = 2score, 3 = 3score, 4=4 score, 5 =5 score, 6 =6 score, 7= 7score, 8 = 8 score

15 HER2 over expression Negative =1, Positive =2

16 Ki67 level <20% =1 >20% =2

17 SISH result Negative =1, Positive =2

18 Molecular subtype Luminal A =1, Luminal B =2, Triple negative =3, HER2 positive = 4

Association among clinical and immunohistochemical factors and molecular subtypes

In our finding, tumor size, grade, stage and pathologic type of tumor have statistically significant association with molecular subtype of tumors. In next lines similar results in previous studies are presented.

Grade of tumor: Statistical analysis showed that molecular subtype of tumor is associated with grade of tumor with p-value <0.001. In our study luminal A tumors have mostly grade I and II, while grade III is seen predominantly in luminal B, triple negative and HER/2 positive sub types. These results is similar finding of San and teammate in Myanmar [19], Paramita et al [20] and Setyawati and colleagues [21] in Indonesia, Li and his group in China [22]. In the study of El Fatemi et al in Morocco [18], study in Kazakhstan [12] and study of Hashmi and colleagues in Pakistan [23], there is a small difference, in their samples, more than half of HER/2 positive cases are in grade II, while in our study are in grade III. This differences maybe related to different study setting, screening program situation and ethnicity.

Ki67: In our study tumors with high proliferation rate are mostly in triple negative and HER/2 positive groups. This finding is in accordance with result of previously mentioned study in Indonesia. In Myanmar and Pakistan studies, mean of ki67 in triple negative and HER/2 positive is higher than luminal subtypes that is proving our findings.

Tumor size: small size tumors (<2cm) composed around 90% of luminal A cases and frequency of tumors (>5cm or extended to chest wall) in HER/2 and triple negative sub type is more. T2 (2-5 cm) is most frequent size in all groups. It means that luminal A has smaller size tumors in comparison to triple negative and HER/2 positive tumors.

This finding is similar to results of Liu et al study in China [24],study of Zavyalova and teammate in Russia [25], Study of El Fatemi and colleagues in Morocco in north Africa with P=0,0003 for association of tumor size and molecular subtype [18]. In El Fatemi study also T2 is most prevalent and highest percentage of T3 and T4 is in HER/2 positive and triple negative subtypes. San and colleagues in Myanmar found that tumors larger than 2 cm were more in HER2 and triple negative subtype [19]. Caldarella et al in Italy, concluded there is significant association for tumor size and luminal B HER/2 negative, triple negative and HER/2 positive subtypes [14].

Stage of tumor: Most of tumors in our study were in stage II, and in all sub type the highest percentage belongs to this stage. Stage III and IV are most frequent in non-luminal A subtypes while stage I and II composed 88% of luminal A tumors.

Same distribution of stage in different molecular groups was found in study of Zavyalova and teammate in Russia. In this research 87% of luminal A are in stage I and II, and triple negative and HER/2 positives tumor have more stage III than other subtypes [25]. In the study of Mehdi and colleagues in Oman, patients with HER/2 sub type and basal cell like (BCL) tumors had higher stage while early stages were observed in luminal types tumors [26] Study of Caldarella et al in Italy found a significant association between molecular sub types and tumor stage [14] In participants of research in China that was conducted by Li

et al, stage 0,I and II composed around 90% of all luminal A cases and stage III is most prevalent in HER/2 positive and BCL tumors [22]. Study in Myanmar showed BCL tumors and HER2, are diagnosed with more advanced stages (stage II, III and IV) [19]. All of this finding are similar to our findings.

Pathologic type of tumor: In our finding percentage of NST in luminal A subtype is less than other three groups and in luminal B is more than other group and most of ILC are in luminal A, and other rare histologic type of tumor has higher percentage in luminal A group. (as presented in figure 3)

In study of Al-thoubaity [13] and Alnegheimish et al [27] in Saudi Arabia similar to these results were found. NST is more frequent in non- luminal A and ILC tumors mostly are luminal A. In Italy, similar to our study ILC and tubular carcinoma are more frequent in luminal A group [14] El Fatemi and colleagues found that there is a significant association between molecular and histologic types of tumor (p<0.00001).in their study similar to our results, ILC percentage in luminal A subtype is higher than other sub types [18]

Study strengths and limitations: One of the strengths of this study is that it is believed to be the first study in Almaty that investigated breast cancer subtypes and the association of determining factors with each other by completing electronic data base information from paper-based data.

Limitations: First of all, the study was done by using medical records and some important information about patients' medical history like menopausal status and obstetric and gynecologic data was not available. Second, data recorded in the electronic data base did not include IHC test results and researcher had to investigate paper based medical records for them. This method tend to omitting around 200 cases from study (in the cases of unsuccessful search) and having a low amount of information about lymph node invasion and distant metastasis of tumor. Third: having no control group

Conclusion

Most common Pathologic type of tumor in this study was NST, ILC and DCIS respectively. Most prevalent molecular subtype of tumors: Luminal B, luminal A, triple negative, HER/2. There was statistically significant association (p-value <0.05) between Molecular subtype and pathologic type of tumor, grade, stage, size and mitotic rate

Refrences:

1. Azamjah N., Soltan-Zadeh Y., Zayeri F. Global trend of breast cancer mortality rate: A 25-year study // Asian Pacific J. Cancer Prev. 2019. Vol. 20, № 7. P. 20152020.

2. Abe O. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials // Lancet. Elsevier Ltd, 2011. Vol. 378, № 9793. P. 771784.

3. Globocan Observatory 2019 W.I., (IARC) I. A. for R. on C., (WHO) W.H.O. Breast Cancer. Source: Globocan 2018 // World Heal. Organ. Int. Agency Res. Cancer. 2019. Vol. 876. P. 2018-2019.

4. Igissinov N. et al. Breast cancer in megapolises of

Kazakhstan: Epidemiological assessment of incidence and mortality // Iran. J. Public Health. 2019. Vol. 48, № 7. P. 1257-1264.

5. Pokazateli onkologicheskoi sluzhby Respubliki Kazahstan za 2019 god. [Electronic resource]. URL: https://onco.kz/wp-content/uploads/2021/02/Pokazateli-onkologicheskoj-sluzhby-Respubliki-Kazahstan-za-2019-g_09.02.2021_compressed-1.pdf (accessed: 07.06.2021).

6. Kaidarova D., Zhylkaidarova A.., Saktaganov M. 12-Years results of the Kazakhstan breast cancer screening programme. 2020. Vol. 30, № Suppl 4. P. 3-4.

7. Moschetta M. et al. Comparison between fine needle aspiration cytology (FNAC) and core needle biopsy (CNB) in the diagnosis of breast lesions // G. di Chir. 2014. Vol. 35, № 7-8. P. 171-176.

8. Han E.S., goleman, daniel; boyatzis, Richard; Mckee A. biopsy interpretation of breast // wolters kluer. 3rd ed. wolters kluwer, 2019.

9. Ohm V.D. et al. WHO classification of Tumors. Breast Tumours // Breast Tumours. 2019. 284 p.

10. Allison K.H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update // J. Clin. Oncol. 2020. Vol. 38, № 12. P. 13461366.

11. Wolff A.C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/ college of American pathologists clinical practice guideline focused update // J. Clin. Oncol. 2018. Vol. 36, № 20. P. 2105-2122.

12. Abiltayeva A. et al. Clinical, Histopathological and Molecular Characteristics of Metastatic Breast Cancer in North-Eastern Kazakhstan: a 10 Year Retrospective Study // Asian Pacific J. Cancer Prev. 2016. Vol. 17, № 10. P. 4797-4802.

13. Al-thoubaity F.K. Molecular classification of breast cancer: A retrospective cohort study // Ann. Med. Surg. 2020. Vol. 49, № October 2019. P. 44-48.

14. Caldarella A. et al. Invasive breast cancer: A significant correlation between histological types and molecular subgroups // J. Cancer Res. Clin. Oncol. 2013. Vol. 139, № 4. P. 617-623.

15. Badowska-Kozakiewicz A.M. et al. The role of oestrogen and progesterone receptors in breast cancer -Immunohistochemical evaluation of oestrogen and progesterone receptor expression in invasive breast cancer in women // Wspolczesna Onkol. 2015. Vol. 19, № 3. P. 220-225.

16. Thang V.H. et al. Cell proliferation measured by Ki67 staining and correlation to clinicopathological

parameters in operable breast carcinomas from vietnamese and Swedish patients // J. Anal. Oncol. 2015. Vol. 4, № 2. P. 58-68.

17. Mandaliya H.A. et al. Breast cancer demographics, screening and survival outcome at a regional Australian cancer centre: a retrospective study // Ann. Oncol. Elsevier Masson SAS, 2016. Vol. 27, № Supplement 6. P. vi479.

18. El Fatemi H. et al. Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: An immunohistochemical profile study from Morocco // Diagn. Pathol. Diagnostic Pathology, 2012. Vol. 7, № 1. P. 1.

19. San T.H. et al. Molecular subtypes of breast cancers from Myanmar women: A study of 91 cases at two pathology centers // Asian Pacific J. Cancer Prev. 2017. Vol. 18, № 6. P. 1617-1621.

20. Paramita S. et al. Luminal B is the most common intrinsic molecular subtypes of invasive ductal breast carcinoma patients in East Kalimantan, Indonesia // Asian Pacific J. Cancer Prev. 2019. Vol. 20, № 8. P. 2247-2252.

21. Setyawati Y. et al. The association between molecular subtypes of breast cancer with histological grade and lymph node metastases in Indonesian woman // Asian Pacific J. Cancer Prev. 2018. Vol. 19, № 5. P. 1263-1268.

22. Li J. et al. Clinicopathological classification and traditional prognostic indicators of breast cancer // Int. J. Clin. Exp. Pathol. 2015. Vol. 8, № 7. P. 8500-8505.

23. Hashmi A.A.. et al. Molecular subtypes of breast cancer in south Asian population by immunohistochemical profile and her2neu gene amplification by fish technique: Association with other clinicopathologic parameters // Breast J. Blackwell Publishing Inc., 2014. Vol. 20, № 6. P. 578-585.

24. Liu Y.H. et al. Unexpected features of breast cancer subtype // World J. Surg. Oncol. World Journal of Surgical Oncology, 2015. Vol. 13, № 1. P. 1-5.

25. Zavyalova M. et al. Clinicopathological features of nonspecific invasive breast cancer according to its molecular subtypes // Exp. Oncol. 2016. Vol. 38, № 2. P. 122-127.

26. Mehdi I., Abdulmasood A. a., Al Bahrani B.J. Breast cancer molecular subtypes in Omani patients: Correlation with age, histology, stage distribution, and outcome—An anaylsis of 542 cases. // J. Clin. Oncol. 2011. Vol. 29, № 27_suppl. P. 219-219.

27. Alnegheimish N.A. et al. Molecular subtypes of breast carcinoma in Saudi Arabia: A retrospective study // Saudi Med. J. 2016. Vol. 37, № 5. P. 506-512.

*Corresponding author:

Maryam Zabihi - MMSc, MD, Lecturer at Dept. of histopathology of Medical Faculty of Herat University, Herat, Afghanistan E-mail: maryam.zabihi1400@gmail.com Phone: +93782994124